The RNA revolution is transforming medicine and biotechnology. From mRNA to non-coding RNA, and from gene editing to next-generation vaccines, we have only begun to unlock their vast potential. At Cisterna, we are committed to advancing this future by providing high-quality RNA products and empowering researchers.
Cisterna is dedicated to advancing the field of RNA-based research, diagnostics and therapeutics by providing exceptionally high-quality RNAs. Our broader mission is to tackle the multifaceted challenges inherent in production of RNAs. These include quality, quantity, cost and delivery lead time. As the applications of RNA continue to evolve, we are committed to providing rapid, innovative and effective solutions to unlock the boundless potential of RNA.
The growing interest in RNA-based applications spanning diagnostics, immunology, and clinical applications has created a critical need for procuring pure and functional RNA for research and development. However, standard production methods generate impurities such as double-stranded RNA (dsRNA), long RNA impurities (LRNA), and short truncated RNA (stRNA). These 'length' impurities can compromise efficacy of downstream applications. Without additional purification, impurities can limit the effectiveness of structure-function studies, gene/RNA editing, targeted protein expression, and other advanced RNA-based solutions.
Cisterna employs cutting-edge chemistry to produce RNA, combining proven methods with proprietary innovations like SPEcific Capture and Cleavage (SPECC) to achieve unparalleled purity.
